According to Sina Finance, Helios emerged from stealth on Wednesday, claiming its blood-testing service can assess health and predict disease risks from a single drop of blood. The 16-month-old startup says its device collects a sample with a light prick and can measure more than 1,000 proteins to assess current health and estimate the risk of conditions including heart failure, blood cancers and Alzheimer’s disease over the next 10 years.
Co-founders Omar Abudayyeh and Jonathan Gootenberg, both 36 and 35 respectively, said Helios raised $2.3 million in seed funding from Y Combinator, venture firm Formation and angel investors. Their third co-founder is Youssef Baroud, a scientist and physician at Massachusetts General Hospital. The founders said prospective investors compared the idea to Theranos but wanted to hear more because they believed it worked.
Helios’s device attaches to the upper arm and collects a drop of blood into a test cartridge. Users send the sealed sample to the company’s Boston laboratory, where protein testing and an AI model are used to assess heart, liver, brain and kidney function and estimate future disease risks. An AI assistant also offers suggestions on diet, lifestyle, supplements and medication. The company says its algorithms draw on more than 80,000 research papers, genetic studies and clinical trials.
Helios plans to offer the test through longevity clinics and concierge doctors in early 2027 for $250 to $600 per test, depending on clinic purchasing volume. It plans to begin direct-to-consumer sales through its website by the end of 2027, but has not set a consumer price.
The company is among businesses developing proteomics tests. Illumina acquired SomaLogic earlier this year, and Thermo Fisher acquired Olink in 2024. Vero Bioscience is also developing a blood test to estimate the biological age of organs. Helios’s founders say proteomics technology differs from Theranos’s, whose claims involved using small blood samples for routine tests.